Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Am J Hematol. 2015 Aug;90(8):732–736. doi: 10.1002/ajh.24072

Figure 2.

Figure 2

(a) OS of newly diagnosed AML patients with intermediate-risk cytogenetics by molecular status (IDH+/NPM1+compared to NPM1+alone). (b) OS of newly diagnosed AML patients with intermediate-risk cytogenetics by molecular status (IDH+/NPM1+compared to IDH+alone). (c) OS of newly diagnosed AML patients with intermediate-risk cytogenetics by molecular status.